Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FOLFOXIRI+ Panitumumab · 1 trial · 1 indication
RECIST
| Arm | Type | Description |
|---|---|---|
| A (FOLFOXIRI + Panitumumab) | EXPERIMENTAL | FOLFOXIRI + Panitumumab |
| B (FOLFOXIRI) | ACTIVE_COMPARATOR | FOLFOXIRI |
| Name | Type | Description |
|---|---|---|
| FOLFOXIRI + Panitumumab | DRUG | irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont. inf. + panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles |
| FOLFOXIRI | DRUG | irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles |
Inclusion Criteria: * Cohort I: Histologically confirmed and definitively inoperable or irresectable metastatic colorectal cancer. Focus on patients with large tumor load at metastatic sites and/or symptomatic metastatic disease * Cohort II: Chance of secondary resection with curative intent define...
Top 20 of 76 competitors